Table 3.
Baseline Medications
| Characteristics | Study Population | BY HK | BY No HK | P value |
|---|---|---|---|---|
| (N=435,512) | (N=6235) | (N=429,277) | ||
| RAASi use, n (%) | ||||
| ACEi | 108,269 (24.9) | 2532 (40.6) | 105,737 (24.6) | <0.0001 |
| ARB | 83,325 (19.1) | 1536 (24.6) | 81,789 (19.1) | <0.0001 |
| MRA | 10,339 (2.4) | 281 (4.5) | 10,058 (2.3) | <0.0001 |
| Other RAASi | 528 (0.1) | 19 (0.3) | 509 (0.1) | 0.0003 |
| RAASi PDC ≥80%, n (%) | ||||
| Stage 1 | 14,196 (53.8) | 101 (58.1) | 14,095 (53.8) | 0.2856 |
| Stage 2 | 55,918 (63.2) | 791 (63.2) | 55,127 (63.2) | 0.9776 |
| Stage 3 | 44,915 (66.1) | 1354 (66.1) | 43,561 (66.1) | 0.9904 |
| Stage 4 | 4053 (61.8) | 306 (65.0) | 3747 (61.5) | 0.1401 |
| Stage 5 | 692 (54.7) | 44 (61.1) | 648 (54.3) | 0.2746 |
| RAASi at optimal dose, n (%) | ||||
| Stage 1 | 6612 (25.1) | 33 (19.0) | 6579 (25.1) | 0.0653 |
| Stage 2 | 26,311 (28.7) | 291 (23.3) | 26,020 (29.8) | <0.0001 |
| Stage 3 | 23,243 (34.2) | 631 (30.8) | 22,612 (34.3) | 0.0008 |
| Stage 4 | 2329 (35.5) | 156 (33.1) | 2173 (35.7) | 0.2719 |
| Stage 5 | 456 (36.0) | 27 (37.5) | 429 (35.9) | 0.8012 |
| Baseline K+ affecting non-RAASi use, n (%) | ||||
| NSAIDs | 90,124 (20.7) | 1335 (21.4) | 88,789 (20.7) | 0.1611 |
| Calcineurin inhibitors | 917 (0.2) | 48 (0.8) | 869 (0.2) | <0.0001 |
| Beta-blockers | 98,485 (22.6) | 2058 (33.0) | 96,427 (22.5) | <0.0001 |
Abbreviations: ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin-receptor blocker; BY, baseline year; K+, potassium; MRA, mineralocorticoid-receptor antagonist; NSAID, nonsteroidal anti-inflammatory drug; PDC, proportion of days covered; RAASi, renin-angiotensin-aldosterone system inhibitors.